Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation
- PMID: 27066008
- PMCID: PMC4811960
- DOI: 10.3389/fimmu.2016.00118
Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation
Abstract
The bone marrow is the origin of all hematopoietic lineages and an important homing site for memory cells of the adaptive immune system. It has recently emerged as a graft-versus-host disease (GvHD) target organ after allogeneic stem cell transplantation (alloHSCT), marked by depletion of both hematopoietic progenitors and niche-forming cells. Serious effects on the restoration of hematopoietic function and immunological memory are common, especially in patients after myeloablative conditioning therapy. Cytopenia and durable immunodeficiency caused by the depletion of hematopoietic progenitors and destruction of bone marrow niches negatively influence the outcome of alloHSCT. The complex balance between immunosuppressive and cell-depleting treatments, GvHD and immune reconstitution, as well as the desirable graft-versus-tumor (GvT) effect remains a great challenge for clinicians.
Keywords: GvHD; GvL; GvT; alloHSCT; bone marrow; bone marrow stroma; memory niche; minor antigen.
Figures

Similar articles
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?Med Hypotheses. 2008;70(6):1186-92. doi: 10.1016/j.mehy.2007.10.008. Epub 2007 Dec 3. Med Hypotheses. 2008. PMID: 18054441
-
Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.Acta Microbiol Immunol Hung. 2010 Dec;57(4):253-347. doi: 10.1556/AMicr.57.2010.4.2. Acta Microbiol Immunol Hung. 2010. PMID: 21183421 Review.
-
[Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].Bull Cancer. 2001 Sep;88(9):908-26. Bull Cancer. 2001. PMID: 11604365 Review. French.
-
Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients.Bone Marrow Transplant. 2002 Jul;30(2):95-102. doi: 10.1038/sj.bmt.1703609. Bone Marrow Transplant. 2002. PMID: 12132048 Clinical Trial.
Cited by
-
Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application.Stem Cells Int. 2018 Jun 14;2018:3057624. doi: 10.1155/2018/3057624. eCollection 2018. Stem Cells Int. 2018. PMID: 30013600 Free PMC article. Review.
-
Empowering the immune fate of bone marrow mesenchymal stromal cells: gene and protein changes.Inflamm Res. 2019 Feb;68(2):167-176. doi: 10.1007/s00011-018-1198-8. Epub 2018 Nov 14. Inflamm Res. 2019. PMID: 30426152
-
Common bone marrow signature in COVID-19-associated multisystem inflammatory syndrome in children: A first-wave small case series experience.Pediatr Blood Cancer. 2022 Nov;69(11):e29919. doi: 10.1002/pbc.29919. Epub 2022 Aug 20. Pediatr Blood Cancer. 2022. PMID: 35986692 Free PMC article.
-
Extracellular Vesicle-Dependent Communication Between Mesenchymal Stromal Cells and Immune Effector Cells.Front Cell Dev Biol. 2020 Nov 6;8:596079. doi: 10.3389/fcell.2020.596079. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33240892 Free PMC article. Review.
-
Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: Implications for HIV gene therapy.PLoS Pathog. 2018 Apr 19;14(4):e1006956. doi: 10.1371/journal.ppat.1006956. eCollection 2018 Apr. PLoS Pathog. 2018. PMID: 29672640 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources